Published in final edited form as:

Org Lett. 2011 February 4; 13(3): 502–505. doi:10.1021/ol102848w.

Total Synthesis of (+)-Isatisine A

Jihoon Lee and James S. Panek*

Department of Chemistry and Center for Chemical Methodology and Library, Development, Metcalf Center for Science and Engineering, Boston University, 590 Commonwealth Avenue, Boston, MA 02215 (USA)

Abstract

Total synthesis of (+)-isatisine A is described based on the application of a silyl-directed Mukaiyama-type [3+2]-annulation for the preparation of a fully substituted furan core. The indole branch forming the quaternary carbon center at C2 was constructed by addition to an intermediate N-acyliminium ion derived from aminal 4. In addition, the fused tetracyclic framework including furan core was built up using modified Buchwald amidation conditions.

The roots and leaves of *Isatis indigotica* Fort. (Cruciferae), a plant species widely cultivated in China and East Asia, have been traditionally used for treatment of viral diseases such as influenza, viral pneumonia, mumps, and hepatitis. In 2007, Chen and co-workers reported isolation of isatisine A (1), which was the only alkaloid among 12 compounds isolated from *I. Indigotica*.¹ Initially, it was isolated as its acetonide derivative 2, and the structure elucidation was established by 1D and 2D NMR experiments, then subsequent X-ray crystallographic analysis secured the structure assignment, as well as the relative and absolute stereochemistries. Biological evaluation of the acetonide derivative 2 reveals that this material exhibits cytotoxicity against C8166 with CC₅₀ = 302 μM and anti-HIV activity of EC₅₀ = 37.8 μM. However, its unusual dioxolane group which is rarely found in natural products led to further investigations to determine whether the acetonide derivative 2 was an artifact formed during the isolation processes using acetone as an eluent, which finally found the actual natural product, isatisine A (1). Recently, the first total synthesis, achieved by Kerr and co-worker, revealed that the assignment of absolute configuration originally provided by Chen's group is antipodal to the natural product.²

The challenging structural features of isatisine A (1) include a fused tetracyclic framework containing a densely substituted furan subunit and two fully substituted carbon centers (C2 & C9) embedded in the core. In addition, an indole branch forms the C-2 quaternary carbon center. Our interest in this alkaloid arose from its challenging tetracyclic skeleton, as well as its potent anti-HIV activity, and a successful approach to developing an efficient synthetic strategy would allow further SAR (structure-activity relationship) and SSAR (stereo-structure activity relationship) studies.

panek@bu.edu.

Supporting Information Available: Experimental details and selected spectral data for all new compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

In our synthetic plan described in scheme 1, we intended to apply a Mukaiyama-type [3+2]-annulation of silane **anti-7** with a suitably functionalized aldehyde to construct tetrahydrofuran core. Subsequent use of a CuI-mediated aryl amidation³ would assemble the tetracyclic skeleton of isatisine A. Accordingly, our retrosynthetic plan began with disconnection of C7a-N to afford an advanced intermediate aryl bromide **3**. Further disconnection occurred at the indole side chain C2-C3', which led to an indole and amination **4**. This intermediate amination would spontaneously form in the course of oxidation of amido-diol. Disconnection between the amide nitrogen N1 and C2 led to protected furan **5**, which possesses the required oxidation state to access the amination **4**. The tetrahydrofuran intermediate **6e** would be constructed from silyl-directed Mukaiyama-type [3+2]-annulation of silane **anti-7** with bromocinnamyl aldehyde **8**.

Mukaiyama [3+2]-annulation strategy to construct functionalized furans was initially developed by Hoppe.⁴ In that context, we have learned that enantioenriched silane reagents bearing C-centered chirality can participate in stereoselective [3+2]-annulation sequence resulting in stereochemically well-defined and highly functionalized furans. In this regard, use of the allyl silanes **7**⁵, prepared from the known epoxy-silanes⁶ in two steps, as a reaction partner afforded silyl-substituted furans with an aryl and aliphatic aldehyde (eq. 1 and 2, figure 2). The annulations took place with high levels of selectivity, which illustrates that the configuration of the C-SiR₃ bond functions as a reliable stereocontrol element during the reaction. In this synthesis, we describe the examples of a silyl-directed [3+2]-annulation and its use in the synthesis of a complex natural product.

Our synthesis began with the preparation of *tetra*-substituted furan **6e** through [3+2]-annulation of silane **anti-7** with 2-bromocinnamyl aldehyde **8** (scheme 2). Thus, using 2.0 equiv of aldehyde **8**⁷ in the presence *p*-TSA (1.0 equiv) at 0 °C afforded desired furan **6e** in 87% yield with high dr (> 20:1). Selective α -bromination in the presence of the conjugated olefin was achieved using PTAB (phenyltrimethylammonium tribromide),⁸ that material was directly treated with TBAF at 0 °C to form an α , β -unsaturated aldehyde. This resulting unstable intermediate unsaturated aldehyde was immediately subjected to oxidation with MnO₂ in the presence of NaCN to afford the α , β -unsaturated methyl ester **9** in 57% yield from tetrahydrofuran **6e**.⁹

The styrene-like olefin of **9** was selectively oxygenated by a catalytic OsO₄ dihydroxylation using 1.0 equiv of NMO, which afforded diol **10** as a 1.5:1 mixture of diastereomers. Formation of the undesired diol was not detected by spectroscopic methods. Conversion of the mixture of diols to a cyclic carbonate and subsequent dihydroxylation of α , β -unsaturated ester **11** still gave 1.5:1 mixture of diastereomers, which means this second dihydroxylation proceeded in a fully stereoselective manner. Subsequent acetonide protection of the resulting diol afforded an intermediate **5** in 67% yield (3 steps) from diol **10**. The relative configuration of bicyclic dioxolane **5** was confirmed by NOE measurement after separation of the two diastereomers.¹⁰

Removal of carbonate of **5** under basic conditions also resulted in the cleavage of the methyl ester to form an intermediate dihydroxy acid which is spontaneously lactonized in CHCl₃ to give a lactone **12** (scheme 3). Treatment of the lactone **12** with anhydrous NH₃ solution in MeOH provided an intermediate amide, which was subjected to oxidation with TEMPO and NaOCl at room temperature.¹¹ As we anticipated, the oxidation of the dihydroxy amide spontaneously underwent cyclization to afford a key intermediate amination **4** as a single diastereomer.

With availability of intermediate hydroxyl-lactam **4**, we turned our attention to the stereoselective indole incorporation. This type of addition is typically carried out under

acidic conditions and presumably proceeds through the formation and trapping of an acyl iminium ion.¹² In this case, it was expected that the indole would approach the iminium ion from the less hindered convex face of the bicyclic. In our synthesis, indole addition was initially conducted under Lewis and Brønsted acidic conditions (In(OTf)₃, BF₃•OEt₂, CSA, and *p*-TSA). However, indole addition to hydroxyl-lactam **4** failed to afford the desired adduct. In order to convert the aminal into a better leaving group, a mesylate was generated *in situ* by treatment of **4** with MsCl (1.2 equiv) at 0 °C, and subsequent addition of a solution of indole (5.0 equiv) in CH₂Cl₂ gave the desired indole adduct **3** in 54% yield as a single diastereomer. Optimal conversion was acquired upon using TFAA instead of MsCl, which afforded **3** in 82% yield as a single diastereomer. The stereochemistry and absolute configuration of the indole branched quarternary carbon center of **3** was confirmed by single crystal X-ray crystallographic analysis (figure 3).

A modified Buchwald intramolecular amidation in the presence of CuI was used to assemble the fused tetracyclic framework. This type of amidation has been studied and used previously by us as a strategy for macrocyclization.¹³ The advanced tetracyclic intermediate **13** was successfully generated through CuI-mediated coupling in 90% yield. Subsequent cleavage of the primary methyl ether¹⁴ and acetonide with excess BBr₃ (9.0 equiv, 3 portions) in the presence of 15-crown-5 and NaI (3.0 equiv) provided (+)-isatisine A (**1**) in 80% yield.

In conclusion, a total synthesis of (+)-isatisine A has been achieved in 13 steps with a 6.9% overall yield starting from allyl silane *anti*-**7**. A key element of our synthesis includes the formation of highly substituted tetrahydrofuran using a silyl-directed Mukaiyama-type [3+2]-annulation strategy. In addition, construction of nitrogen-containing tetracyclic skeleton through CuI-mediated amidation demonstrated that this method can be useful for fused polycyclic systems in complex molecule synthesis. Further studies and applications of stereoselective [3+2]-annulation are currently underway.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Financial support was obtained from NIH CA 53604. We are grateful to Dr. Paul Ralifo, Dr. Norman Lee, and Dr. Jeffrey Bacon (Chemical Instrumentation Center at Boston University) for helpful discussions and assistance with NMR, HRMS, and X-ray crystallographic analysis experiments.

References

1. Liu JF, Jiang ZY, Wang RR, Zheng YT, Chen JJ, Zhang XM, Ma YB. *Org Lett.* 2007; 9:4127–4129. [PubMed: 17850153]
2. (a) Karadeolian A, Kerr MA. *Angew Chem Int Ed.* 2010; 49:1133–1135. (b) Karadeolian A, Kerr MA. *J Org Chem.* 2010; 75:6830–6841. [PubMed: 20857988]
3. (a) Klapars A, Antilla JC, Huang X, Buchwald SL. *J Am Chem Soc.* 2001; 123:7727–7729. [PubMed: 11481007] (b) Klapars A, Huang X, Buchwald SL. *J Am Chem Soc.* 2002; 124:7421–7428. [PubMed: 12071751]
4. (a) Hoppe D, Kramer T, Erdbrügger CF, Egert E. *Tetrahedron Lett.* 1989; 30:1233–1236. (b) Brüns A, Wibbeling B, Fröhlich R, Hoppe D. *Synthesis.* 2006:3111–3121. (c) Kollmann S, Fröhlich R, Hoppe D. *Synthesis.* 2007:883–892. (d) Becker J, Fröhlich R, Salorinne K, Hoppe D. *Eur J Org Chem.* 2007:3337–3348.
5. For the preparation of *syn* and *anti*-ethoxy allyl silane **7**, see the Supporting Information.
6. Lowe JT, Youngsaye W, Panek JS. *J Org Chem.* 2006; 71:3639–3642. [PubMed: 16626157]

7. Kim JH, Lee S, Kwon MG, Park YS, Choi SK, Kwon BM. *Synth Commun.* 2004; 34:1223–1228.
8. Ager DJ, Fleming I, Patel SK. *J Chem Soc, Perkin Trans 1.* 1981:2520–2526.
9. Corey EJ, Posner GHJ. *Am Chem Soc.* 1968; 90:5616–5617.
10. For the spectroscopic analysis, see the Supporting Information.
11. (a) Slee DH, Romano SJ, Yu J, Nguyen TN, John JK, Raheja NK, Axe FU, Jones TK, Ripka WC. *J Med Chem.* 2001; 44:2094–2107. [PubMed: 11405647] (b) Tron GC, Pagliai F, Grosso ED, Genazzani AA, Sorba G. *J Med Chem.* 2005; 48:3260–3268. [PubMed: 15857132]
12. (a) Skarpos H, Vorob'eva DV, Osipov SN, Odinet IL, Breuer E, Röschenenthaler GV. *Org Biomol Chem.* 2006; 4:3669–3674. [PubMed: 16990943] (b) Abid M, Teixeira L, Török B. *Org Lett.* 2008; 10:933–935. [PubMed: 18254637] (c) Higuchi K, Sato Y, Tsuchimochi M, Sugiura K, Hatori M, Kawasaki T. *Org Lett.* 2009; 11:197–199. [PubMed: 19055376]
13. (a) Wrona IE, Gabarda AE, Evano G, Panek JS. *J Am Chem Soc.* 2005; 127:15026–1502. [PubMed: 16248632] (b) Qin HL, Panek JS. *Org Lett.* 2008; 10:2477–2479. [PubMed: 18489177]
14. (a) Niwa H, Hida T, Yamada K. *Tetrahedron Lett.* 1981; 22:4239–4240. (b) Su Q, Panek JS. *J Am Chem Soc.* 2004; 126:2425–2430. [PubMed: 14982450]

Figure 1.
Revised structure of isatisine A (**1**) and original proposed structure of its acetonide **2**.

Figure 2.
Asymmetric Mukaiyama-type [3+2]-annulation of *anti*- and *syn*-ethoxy allyl silane **7**

Figure 3.
X-Ray structure of the indole adduct **3**

Scheme 1.
Retrosynthetic analysis of (+)-isatisine A (**1**)

Scheme 2.
Preparation of intermediate **5**

Scheme 3.
Completion of synthesis of (+)-isatisine A (**1**)